Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
1.01T
Market cap1.01T
Price-Earnings ratio
52.60
Price-Earnings ratio52.60
Dividend yield
0.56%
Dividend yield0.56%
Average volume
2.52M
Average volume2.52M
High today
$1,104.52
High today$1,104.52
Low today
$1,063.15
Low today$1,063.15
Open price
$1,086.83
Open price$1,086.83
Volume
2.56M
Volume2.56M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

As of today, Eli Lilly(LLY) shares are valued at $1,064.00. The company's market cap stands at 1.01T, with a P/E ratio of 52.60 and a dividend yield of 56.4%.

On 2026-01-11, Eli Lilly(LLY) stock moved within a range of $1,063.15 to $1,104.52. With shares now at $1,064.00, the stock is trading +0.1% above its intraday low and -3.7% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 2.56M, versus its average volume of 2.52M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

Nasdaq 10h
This Healthcare Stock Could Be One of the Best Companies to Own in 2026

Key Points Eli Lilly should see more strong results thanks to its key growth driver, tirzepatide. The drugmaker can fend off the rising competition in the wei...

This Healthcare Stock Could Be One of the Best Companies to Own in 2026
24/7 Wall St. 1d
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Eli Lilly (NYSE:...

TipRanks 2d
Micron, Broadcom, Block, Eli Lilly, Marvell: Insider Shake-Up

Insiders have been trading these 5 stocks: ((MU)), ((AVGO)), ((XYZ)), ((LLY)) and ((MRVL)). Here is a breakdown of their recent trades and their value. Claim 7...

Analyst ratings

79%

of 29 ratings
Buy
79.3%
Hold
17.2%
Sell
3.4%

More LLY News

Simply Wall St 2d
Assessing Revvity’s Valuation After New AI Partnership With Eli Lilly

Advertisement What Lilly’s AI tie-up could mean for Revvity stock Revvity (RVTY) just announced a collaboration with Eli Lilly that puts Lilly’s TuneLab AI an...

Assessing Revvity’s Valuation After New AI Partnership With Eli Lilly
Investor's Business Daily 2d
Eli Lilly Stock Back In Focus After Long Slumber

Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences 5:46 AM ET Highly rated Eli Lilly stock is this week's Big Cap 20 pick to watch as it at...

Eli Lilly Stock Back In Focus After Long Slumber
CNBC 2d
Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight-loss pill

Amazon announced Friday it now offers Novo Nordisk 's Wegovy weight-loss pill through its digital pharmacy. Novo Nordisk began rolling out an oral version of i...

Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight-loss pill
Simply Wall St 2d
Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR?

On 9 January 2026, Schrödinger, Inc. announced a collaboration with Eli Lilly’s TuneLab platform, integrating TuneLab’s AI-driven drug discovery workflows into...

Is Schrödinger’s TuneLab AI Integration Reshaping the Investment Case For SDGR?
Seeking Alpha 2d
Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery

Schrödinger (SDGR) and Revvity (RVTY) on Friday announced collaborations with Eli Lilly (LLY) to integrate their respective drug development software offerings...

Eli Lilly in pact with Schrödinger, Revvity for AI-driven drug discovery
Benzinga 2d
Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight

On Thursday, Eli Lilly and Co. (NYSE:LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz...

Eli Lilly Study Finds Zepbound Dual Treatment Improves Arthritis, Helps Patients Lose Weight
Nasdaq 2d
Revvity, Lilly Partner To Expand Access To AI Drug Discovery Models

(RTTNews) - Revvity, Inc. (RVTY) on Friday announced a collaboration with Eli Lilly and Company (LLY) to make Lilly TuneLab, Lilly's AI-driven predictive modeli...

Revvity, Lilly Partner To Expand Access To AI Drug Discovery Models

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.